Aims and scope
Thorax is one of the world’s leading respiratory medicine journals, publishing clinical and experimental research articles on respiratory medicine, paediatrics, immunology, pharmacology, pathology, and surgery. Thorax seeks to publish significant advances in scientific understanding, which are likely to impact on clinical practice. This includes articles concerning basic and translational mechanisms with application to clinical material (cell and molecular biology, genetics, epidemiology, and immunology).
Thorax is co-owned by the British Thoracic Society and BMJ.
Journal statistics 2015
8% for Original Research
Instant Reject rate
54% for all papers, receiving a decision within 1-3 days
Time from Submission to First Decision
Time from Submission to Final Decision
Time from Acceptance to Publication
17 days (online)
3 months (print)
Index Medicus (Medline), Science Citation Index, ISI Current Contents (Clinical Medicine/Life Sciences), Excerpta Medica (Embase), BIOSIS Previews
For all contact information please refer to the Contact Us page.
Please refer to the Instructions for Authors.
Rights and permissions
Thorax is provided as a benefit to members of the British Thoracic Society (BTS).
BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.
The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting accurate, transparent reporting of research studies. The BMJ Group is a sponsor of its activities.
BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.
Related BMJ sites